Piper Sandler analyst Yasmeen Rahimi initiated coverage with a Buy rating on aTyr Pharma (LIFE – Research Report) today and set a price target of $20.00. The company’s shares opened today at $1.16.
According to TipRanks, Rahimi is a 3-star analyst with an average return of 1.2% and a 33.08% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Structure Therapeutics, Inc. Sponsored ADR, and Cytokinetics.
Currently, the analyst consensus on aTyr Pharma is a Strong Buy with an average price target of $22.33, representing a 1,825.00% upside. In a report released today, JonesTrading also maintained a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
LIFE market cap is currently $65.6M and has a P/E ratio of -0.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
aTyr Pharma (LIFE) Company Description:
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
- aTyr Pharma to Present at November Investor Conferences
- aTyr Pharma announces dosing of first patient in Phase 2 EFZO-CONNECT study
- aTyr Pharma presents efzofitimod data
- aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
